LIGAND PHARMACEUTICALS (LGND)
LIGAND PHARMACEUTICALS Profit Margin: 24.56%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LGND Profit Margin Rankings
| Overall | 92nd percentile | 318 of 4397 |
| Sector | 94th percentile | 25 of 469 in Healthcare |
| Industry | 91st percentile | 1 of 12 in Drugs - Generic |
LGND Profit Margin Range, Past 5 Years
| Minimum | -562.0% | Dec 2008 |
| Maximum | 38.37% | Dec 2011 |
| Average | -78.70% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these LGND related companies
LGND News
Ligand Pharmaceuticals (LGND) Says Glaxo (GSK) Submits Regulatory Apps for Promacta/Revolade
May 30, 10:17AM Street Insider
May 30, 10:17AM Street Insider
$LGND may extend last week's move to 14.50, we got buy signal 5/24 which may last 14 days. Target price 14.50
about 3 days ago by woowtrading
about 3 days ago by woowtrading
$LGND Insider Sale: $2.3M of stock sold by David Knott on May 24, 2012 http://stks.co/3zbT
about 5 days ago by MarketBrief
about 5 days ago by MarketBrief
$LGND Ligand partner abstracts posted for ASCO 2012 for Promacta, Kyprolis, CUDC-101 and ME-143 http://stks.co/3sZF
about 13 days ago by Ligand_LGND
about 13 days ago by Ligand_LGND
$LGND presents at Merril Lynch Healthcare on Thursday, Jeffries on June 4, and has a panel date on 6/20.
about 15 days ago by britepathos
about 15 days ago by britepathos
CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4
May 14, 12:21PM Business Wire
May 14, 12:21PM Business Wire
Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17
May 07, 3:15PM Business Wire
May 07, 3:15PM Business Wire
$LGND to report earnings results on May 2nd at 4:30 pm ET. Webcast/cc at: http://stks.co/3Z5U
about 32 days ago by abubnic
about 32 days ago by abubnic
$LGND This week's top stories in technology 4/23-4/27 http://stks.co/3Z4k
about 32 days ago by ericjones12398
about 32 days ago by ericjones12398
$LGND Ligand partner Merck posted May 2012 as start date for P3 Dinaciclib evaluation study on http://stks.co/3YYR http://stks.co/3YYS
about 33 days ago by Ligand_LGND
about 33 days ago by Ligand_LGND
$LGND Ligand Captisol partner Onyx announced FDA Advisory Committee, ODAC, to review NDA for Carfilzomib on June 20 http://stks.co/3WrZ
about 34 days ago by Ligand_LGND
about 34 days ago by Ligand_LGND
$LGND Ligand partner GSK reported Promacta sales of $43M in Q1, more than doubling compared to $19 million in Q1 2011, http://stks.co/3VQE
about 35 days ago by Ligand_LGND
about 35 days ago by Ligand_LGND
$LGND Clinical study of Ligand’s LGD-4033 (SARM) program published in most recent Journal of Gerontology http://stks.co/3Edn
about 55 days ago by Ligand_LGND
about 55 days ago by Ligand_LGND
@ChartSwingTrade I would say $HSFT,$LGND, $GMAN, $KIRK look great to me even before scanning for tomorrow
about 79 days ago by ivan_bg
about 79 days ago by ivan_bg
$LGND over 16 looks like a decent swing trade to ~20. Beware It's lightly traded.
about 80 days ago by Contrarius
about 80 days ago by Contrarius
$LGND Ligand partner Onyx completes ASPIRE P3 enrollment for Carfilzomib; completion of NDA review expected by July 27 http://stks.co/2Zk8
about 93 days ago by Ligand_LGND
about 93 days ago by Ligand_LGND
Ligand to Present at the Citi Global Health Care Conference on February 28th
Feb 21, 12:30PM Business Wire
Feb 21, 12:30PM Business Wire
Ligand (LGND) Licenses DARA to Retrophin; May Get Up to $75M in Milestone Payments
Feb 21, 8:51AM Street Insider
Feb 21, 8:51AM Street Insider
$LGND is at $14.700 and is forming a base right now. When $LGND breaks above $15.910 on at least 174,027 share volume day,buy $LGND.
about 110 days ago by sundeeptrade
about 110 days ago by sundeeptrade
Ligand to Present at the BIO CEO and Investor Conference on February 13
Feb 09, 12:45PM Business Wire
Feb 09, 12:45PM Business Wire
Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance
Feb 07, 4:49PM Street Insider
Feb 07, 4:49PM Street Insider
Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development
Feb 07, 8:00AM Business Wire
Feb 07, 8:00AM Business Wire
Ligand Pharma (LGND) Completes PG-Free Melphalan Phase II, Issues Update
Feb 02, 6:47AM Street Insider
Feb 02, 6:47AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LGND | 12.81 | +0.15 | +1.18% | 249.15M |
| LGL | 6.91 | +0.05 | +0.73% | 17.83M |
| LGI | 13.60 | +0.10 | +0.74% | |
| LGF | 12.75 | -0.16 | -1.24% | 1.774B |
| LGCY | 25.55 | -0.53 | -2.03% | 1.250B |
| LG | 38.29 | +0.10 | +0.26% | 858.89M |
| LFUS | 57.82 | -0.95 | -1.62% | 1.270B |
| LFL | 23.77 | -0.54 | -2.22% | 8.273B |
| LFC | 34.95 | -1.19 | -3.29% | 17.93B |
| LF | 10.37 | -0.07 | -0.67% | 577.96M |